This session will review and summarize trends in infectious and RCDAD testing and screening practices. We will also review the challenges which arise in essential testing procedures like NAT, serology and more. As we discuss the challenges, we will also review the impact that poor or insufficient samples may have on the outcome of such tests, and finally, we will elaborate upon the method of reading and interpreting these tests and reports.
- What are some different types of serology testing methodologies?
- What is a “window period” with an infectious disease?
- How do initially-reactive results affect testing algorithms?
- How does poor sample quality affect testing and results?
- What can the lab and the client do to minimize poor sample quality?
- What challenges does the testing lab have to overcome?
- How do you interpret a serology screening report?
Rod Hale, Director of Laboratory Operations at VRL-Eurofins, graduated magna cum laude from Utah State University in 1992 with a Bachelor’s of Science in Applied Biology. In 1997, he earned his Masters of Science in Medical and Molecular Genetics from Indiana University. He has 20 years’ experience in the Human Cell & Tissue Product (HCT/P) industry. The first 12 years were spent at Laboratories At Bonfils, (which became LABS, Inc.). Rod performed various immunological and molecular tests for the screening of eye, tissue, organ and other transplant donors, eventually becoming the manager of the Infectious Disease department, where he successfully implemented and oversaw the testing logistics that enabled the small regional lab to achieve nationwide growth. In 2010, he helped establish the human-screening division of VRL, which has since become the leader in HCT/P screening.
NAT & Serology Testing & Challenges
Speaker: Rod Hale, MS
Day: June 6, 2018
Time: 2:00 p.m. - 3:00 p.m. EST